Shares of Aratana Therapeutics (NASDAQ:PETX), a small-cap company focused on animal health, dropped more than 50% in September after the company released disappointing clinical trial results.

Is this drop a buying opportunity? See the presentation below for details.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.